Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $10.4600 (1.36%) ($9.9500 - $10.4700) on Thu. Apr. 16, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.03% (three month average) | RSI | 48 | Latest Price | $10.4600(1.36%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 0.7% a day on average for past five trading days. | Weekly Trend | TGTX advances 2.5% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(63%) ARKG(57%) ARKK(54%) IBB(54%) IBUY(52%) | Factors Impacting TGTX price | TGTX will decline at least -3.515% in a week (0% probabilities). VIXM(-32%) VXX(-31%) UUP(-15%) TLT(-1%) DRIV(-0%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.515% (StdDev 7.03%) | Hourly BBV | 0 () | Intraday Trend | 0.3% | | | |
|
5 Day Moving Average | $10.32(1.36%) | 10 Day Moving Average | $9.97(4.91%) | 20 Day Moving Average | $9.66(8.28%) | To recent high | -34.6% | To recent low | 46.5% | Market Cap | $1.325b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |